Jacobson L, Brooke S, Sapolsky R
Department of Biological Sciences, Stanford University, CA 94305-5020.
Brain Res. 1993 Oct 15;625(1):84-92. doi: 10.1016/0006-8993(93)90140-i.
It is unclear whether in vitro corticosteroid receptor binding assays have used inappropriately high concentrations of synthetic corticosteroid competitors, thereby potentially introducing error into estimates of type I (mineralocorticoid) and type II (glucocorticoid) receptor binding. To determine more accurately the concentration of blockers necessary to discriminate between these two sites, we have derived Ki values for the competition of dexamethasone, RU 28362 and RU 26752 for [3H]corticosterone and [3H]dexamethasone binding in rat hippocampus. Non-specific binding of both radioligands was defined with unlabeled dexamethasone to exclude transcortin. The type II agonist RU 28362 competed for only a portion of [3H]corticosterone binding, exhibiting a Ki of 0.5 nM for this binding. In contrast, RU 28362 fully competed all binding of a saturating concentration of [3H]dexamethasone, even though [3H]dexamethasone also recognized type I receptors, defined as specific [3H]corticosterone binding in the presence of 80 nM RU 28362. RU 28362 competition for [3H]dexamethasone binding exhibited characteristics of a 2-site interaction, with Kis of 0.3 and 194 nM. The type I receptor antagonist RU 26752 competed less effectively for [3H]corticosterone and [3H]dexamethasone binding, but nonetheless competed fully within a 1000-fold concentration range. Even at a level less than 125 x its Ki for type I binding, RU 26752 still inhibited virtually all type II receptor binding by [3H]corticosterone. We conclude that type I and II receptors in rat brain are best distinguished using [3H]corticosterone as the labelling ligand, with cold RU 28362 and dexamethasone to eliminate binding to type II and transcortin sites, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
目前尚不清楚体外皮质类固醇受体结合试验是否使用了过高浓度的合成皮质类固醇竞争剂,从而可能在I型(盐皮质激素)和II型(糖皮质激素)受体结合的估计中引入误差。为了更准确地确定区分这两个位点所需的阻断剂浓度,我们得出了地塞米松、RU 28362和RU 26752在大鼠海马中竞争[3H]皮质酮和[3H]地塞米松结合的Ki值。两种放射性配体的非特异性结合用未标记的地塞米松定义以排除皮质素转运蛋白。II型激动剂RU 28362仅竞争部分[3H]皮质酮结合,该结合的Ki为0.5 nM。相比之下,RU 28362完全竞争饱和浓度的[3H]地塞米松的所有结合,尽管[3H]地塞米松也识别I型受体,定义为在80 nM RU 28362存在下的特异性[3H]皮质酮结合。RU 28362对[3H]地塞米松结合的竞争表现出双位点相互作用的特征,Ki分别为0.3和194 nM。I型受体拮抗剂RU 26752对[3H]皮质酮和[3H]地塞米松结合的竞争效果较差,但在1000倍浓度范围内仍能完全竞争。即使在低于其I型结合Ki的125倍水平时,RU 26752仍几乎抑制了[3H]皮质酮的所有II型受体结合。我们得出结论,大鼠脑中的I型和II型受体最好用[3H]皮质酮作为标记配体来区分,用冷的RU 28362和地塞米松分别消除与II型和皮质素转运蛋白位点的结合。(摘要截断于250字)